Dark Forest Capital Management LP acquired a new position in shares of CME Group Inc. (NASDAQ:CME - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,055 shares of the financial services provider's stock, valued at approximately $601,000.
A number of other institutional investors and hedge funds have also made changes to their positions in CME. Ameriprise Financial Inc. increased its holdings in CME Group by 11.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,283,196 shares of the financial services provider's stock valued at $1,038,676,000 after purchasing an additional 537,758 shares in the last quarter. AQR Capital Management LLC increased its holdings in CME Group by 10.5% in the 2nd quarter. AQR Capital Management LLC now owns 1,229,566 shares of the financial services provider's stock valued at $240,331,000 after purchasing an additional 117,263 shares in the last quarter. AXA S.A. increased its holdings in CME Group by 70.3% in the 2nd quarter. AXA S.A. now owns 494,604 shares of the financial services provider's stock valued at $97,239,000 after purchasing an additional 204,147 shares in the last quarter. Caxton Associates LP increased its holdings in CME Group by 16.9% in the 2nd quarter. Caxton Associates LP now owns 70,156 shares of the financial services provider's stock valued at $13,793,000 after purchasing an additional 10,156 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in CME Group in the 2nd quarter valued at $2,315,000. 87.75% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:CME opened at $218.30 on Friday. The company has a market capitalization of $78.60 billion, a price-to-earnings ratio of 24.84, a price-to-earnings-growth ratio of 8.74 and a beta of 0.55. CME Group Inc. has a one year low of $190.70 and a one year high of $223.80. The stock has a 50-day simple moving average of $209.70 and a 200 day simple moving average of $207.57. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.02 and a current ratio of 1.02.
CME Group (NASDAQ:CME - Get Free Report) last issued its earnings results on Wednesday, July 24th. The financial services provider reported $2.56 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.03. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the previous year, the firm posted $2.30 earnings per share. CME Group's quarterly revenue was up 12.7% compared to the same quarter last year. Sell-side analysts predict that CME Group Inc. will post 9.94 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Shareholders of record on Monday, September 9th were paid a $1.15 dividend. The ex-dividend date was Monday, September 9th. This represents a $4.60 dividend on an annualized basis and a yield of 2.11%. CME Group's payout ratio is currently 52.33%.
Several analysts recently issued reports on CME shares. Deutsche Bank Aktiengesellschaft increased their price target on CME Group from $193.00 to $200.00 and gave the company a "hold" rating in a report on Thursday, August 15th. Bank of America lowered CME Group from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $212.00 to $177.00 in a research report on Tuesday, September 3rd. Royal Bank of Canada started coverage on CME Group in a research report on Friday. They set a "sector perform" rating and a $235.00 target price on the stock. Barclays lifted their target price on CME Group from $208.00 to $209.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 25th. Finally, TD Cowen started coverage on CME Group in a research report on Thursday. They set a "hold" rating and a $221.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $212.54.
Check Out Our Latest Stock Analysis on CME Group
In other CME Group news, Director Bryan T. Durkin sold 7,593 shares of CME Group stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $214.59, for a total value of $1,629,381.87. Following the completion of the transaction, the director now directly owns 55,607 shares in the company, valued at $11,932,706.13. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Lynne Fitzpatrick sold 754 shares of the business's stock in a transaction that occurred on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total transaction of $163,610.46. Following the completion of the transaction, the chief financial officer now directly owns 13,261 shares in the company, valued at $2,877,504.39. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bryan T. Durkin sold 7,593 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $214.59, for a total value of $1,629,381.87. Following the transaction, the director now owns 55,607 shares of the company's stock, valued at $11,932,706.13. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.